Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combining ablative fractional CO2 laser treatment with topical minoxidil significantly improved frontal hairline regrowth and patient satisfaction in men with androgenetic alopecia compared to using minoxidil alone, without serious adverse effects.

This review discusses folliculotropic mycosis fungoides, highlighting its diagnostic criteria and therapeutic strategies based on disease staging, but does not report new clinical findings.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

This review indicates that while microneedling shows potential for managing androgenetic alopecia, particularly in combination with other treatments, the existing evidence is of low to moderate quality, and more robust trials are needed to confirm its clinical efficacy and safety.

This review highlights a disconnect between mechanistic insights and physiological relevance in preclinical models of hair loss disorders and suggests a shift toward more human-relevant systems could enhance translational research, despite limitations in existing models like transgenic mice and xenografts.

In this prospective study, researchers identified advanced age, androgenetic alopecia, high levels of lactate dehydrogenase and dihydrotestosterone, and low levels of adenosine triphosphate as independent risk factors for posttransplant telogen effluvium, offering insights for optimizing surgical strategies to reduce PTE risk.

This study found that a novel topical dutasteride lotion, FOL100, demonstrated excellent safety, tolerability, and usability with promising signs of clinical benefit for mild-to-moderate male pattern baldness.

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

This review found that circulating dihydrotestosterone (DHT) consistently distinguishes men with androgenetic alopecia from controls, suggesting a key role in the condition's biology and potential therapeutic targeting.

This study suggests that autologous platelet concentrates may improve inflammatory activity, disease control, and hair regrowth in primary cicatricial alopecia, but the evidence is limited by small sample sizes and study quality.

This study found that Pinus massoniana needles extract may promote hair regrowth in a mouse model of androgenetic alopecia, potentially by reducing oxidative stress and affecting immune, metabolic, and apoptosis-related pathways.

In this study, researchers found that among 7,761 patients with androgenetic alopecia, behaviors such as insufficient sleep, poor dietary habits, alcohol consumption, heavy physical labor, and specific hairstyling choices were associated with increased severity of hair loss.

This review discusses female pattern hair loss as an early marker of hormonal imbalance and evaluates hormonal and lifestyle interventions, but reports no new clinical results.

In this hospital-based cross-sectional study, researchers found that alopecia is more prevalent in younger patients, with alopecia areata and lichen planopilaris being the most common types among noncicatricial and cicatricial cases, respectively; additionally, thyroid abnormalities were frequently associated with both types of alopecia.

In this retrospective study, dupilumab treatment in young children with alopecia areata and atopic features was linked to full hair regrowth without serious adverse events, though findings from this small cohort should be interpreted cautiously.

This study found that only a small percentage of alopecia areata patients treated with baricitinib in real-world settings would have met the eligibility criteria used in clinical trials.

This study found that a hair serum containing Acanthus ebracteatus extract improved hair regrowth in men with androgenic alopecia, increasing hair count and density of anagen hairs over a 6-month period, with combination treatments showing early effectiveness.

This study reports that intramuscular compound betamethasone may offer rapid, short-term reduction in hair shedding for patients with telogen effluvium, particularly within a week, but often requires repeated treatments; only mild side effects were observed.

This study found that a shampoo containing 1% selenium sulfide and 1% salicylic acid significantly improved the clinical signs and symptoms of seborrheic dermatitis and dandruff over an 8-week period.

This study found that baricitinib significantly reduced alopecia severity in JAK inhibitor-naïve patients compared to those previously treated with tofacitinib, indicating that switching JAK inhibitors can be safe and may be beneficial for selected patients with partial prior responses.

This study found that adding low-dose oral minoxidil to standard treatment for lichen planopilaris was safe but did not significantly improve hair density or thickness, although minor hair regrowth was observed in some scarring areas.

This retrospective study reported significant improvements in keloid scars among 60 patients treated with punch excision and superficial X-ray, with lower Vancouver Scar Scale and Patient and Observer Scar Assessment Scale scores a year post-treatment and no severe adverse reactions observed.

This review article reports that oxidative stress is a key mechanism in the development of androgenetic alopecia, interacting with genetic and hormonal factors to damage hair follicle cells and potentially informing future treatment strategies.

This study found that ablative fractional carbon dioxide laser treatment improved skin fibrosis, reduced skin hardening, and enhanced hair follicle growth in localized scleroderma patients, with significant improvements across several clinical measures and no severe adverse effects observed.

In this retrospective study, baricitinib effectively improved alopecia areata in 78.7% of patients by the end of treatment, with significant hair regrowth observed, particularly in those with disease duration of four years or less, and showed no serious adverse events.

In this study, the combination of topical minoxidil and betamethasone was found to be more effective for hair regrowth and patient satisfaction in alopecia areata patients compared to betamethasone alone or with herbal oils, though further randomized trials are recommended.

This study found that nonablative Er:YAG laser therapy effectively improved hair appearance for patients with androgenetic alopecia, with most participants reporting increased satisfaction and no adverse reactions, following six biweekly sessions.

In this review, researchers explored key mechanisms underlying androgenetic alopecia, revealing how hormonal, oxidative, inflammatory, and lipid dysregulation suppress hair growth pathways and suggesting new therapeutic targets such as DP2 antagonists and microbiome modulators.

In this study, treatment with fractional CO2 laser combined with recombinant humanized type III collagen led to significantly better improvements in atrophic acne scars compared to laser treatment with saline, attributed to collagen upregulation and MAPK pathway activation in human dermal fibroblasts.

In this study, AA patients and healthy controls showed no significant difference in carotid intima-media thickness, but AA patients had higher diastolic blood pressure and fasting blood glucose levels, indicating potential cardiovascular risks.